May 16, 2011 — GE Healthcare today received the Price Performance Value Leadership Award in PET (positron emission tomography) for North America 2011 from global research organization Frost & Sullivan.
According to Frost & Sullivan, the Price Performance Value Leadership Award is a prestigious recognition of GE Healthcare’s accomplishments in PET. Based on Frost & Sullivan’s analysis of the latest value-based systems currently being offering by PET/CT manufacturers, GE Healthcare’s Optima PET/CT 560 was found to offer a higher price performance value than any other system on the market.
First to the market with PET/CT in 2001, GE Healthcare has built upon its excellence in PET/CT with the Optima PET/CT 560, an innovative scanner designed to address the demands of today’s healthcare environment. Combining superb image quality, high productivity and a patient friendly experience, the Optima PET/CT 560 can continuously deliver ongoing value over time. The system offers efficiency and investment protection with the capability to grow with the future needs of the clinical practice. From the uninterrupted full head to toe exam to the remarkable dose reduction features, the Optima PET/CT 560 was designed to help physicians put patients’ needs first. It includes advanced VUE Point HD intelligent 3-D iterative reconstruction technique to enhance resolution for uncompromised image quality that can help enable clinicians to confidently detect small lesions and increase quantitative accuracy.
According to Frost & Sullivan, despite growing evidence pointing to its superior diagnostic capabilities in many applications within oncology and cardiology, PET/CT’s higher costs have been a deterrent to widespread adoption of this technology since its commercial introduction in 2001. Frost & Sullivan notes that the recent downturn in the U.S. economy and uncertainties surrounding healthcare reform further exasperated this challenge, as these circumstances intensified demand in the market for the more affordable imaging equipment that provides adequate performance in clinically relevant applications. Frost & Sullivan also notes the significant cost-barrier in PET/CT has prompted manufacturers of this technology to become more focused on developing systems that provide the highest performance at the lowest price point possible.
For more information: www.gehealthcare.com
July 11, 2022 
